SMAD7 and myeloid sarcoma: As a therapeutic tool in MS subjects, FAE selectively reduces miR-21 transcripts in Th17 cells and indirectly increases its target—the small mothers against decapentaplegic homolog 7 (SMAD7)—an inhibitor of their differentiation [Table 1; (144, 146)].